

	London - (untreated; No ADT)	London – ADT treated	Harvard Non-responders	Harvard Responders
Age at diagnosis				
40-59	2	2	5	4
60-79	3	3	5	5
80-99	1	0	0	0
Gleason score at RP/TURP				
6	1	0	0	0
7	2	1	1	2
8	0	1	4	2
9	3	2	5	5
10	0	1	0	1
Stage at RP/TURP				
T0	0	0	0	5
T1	0	0	0	0
T2	1	0	0	5
T3a	2	0	6	0
T3b	1	2	4	0
T4	0	2	0	0
UNK	2	1		
Metastatic at RP/TURP:				
Yes	0	3	0	0
No	6	2	0	0
<u>Treatments</u>				
<i>ICR:</i>				
LHRH inhibitors (Leuprolide, Goserelin or Triptorelin) Dana Faber Cancer	6	5	-	-
<i>Institute:</i>				
Group 1: Abiraterone + Prednisone + Enzalutamide + Leuprolide	-	-	3	3
Group 2: Enzalutamide + Leuprolide	-	-	3	1
Group 3: Abiraterone + Prednisone + Apalutamide + Leuprolide	-	-	1	2
Group: Abiraterone + Prednisone + Leuprolide	-	-	3	4

Suppl. Table. Clinicopathological data for the anonymised patient groups whose tumor sections were stained and analysed in Figures 2 and 3. These were supplied by the Institute of Cancer Research (ICR) in London, UK and the Dana Faber Cancer Institute in Boston, USA. Abbreviations used: ADT, androgen deprivation therapy; RP, radical prostatectomy; TURP, Transurethral resection of the prostate, LHRH, luteinising hormone-releasing hormone.